CSIR-CDRI and Dr. Reddy’s Laboratories partner to develop high-value generics in API value chain
Bureau chief R L Pandey
Lucknow। Central Drug Research Institute (CDRI), a constituent Laboratory of Council of Scientific and Industrial Research (CSIR) and Dr. Reddy's Laboratories Ltd. (Dr. Reddy’s), a global pharmaceutical company headquartered in Hyderabad, India have entered into an agreement for the development of high-value generics in Active Pharmaceutical Ingredients (APIs) value chain (starting materials & Intermediates). The aim of the collaboration is to develop cost-effective and industrially viable processes for selected generic drugs. A group of expert synthetic chemists from CSIR-CDRI and Dr. Reddy’s will work jointly to deliver the project goals. Upon successful execution, the collaboration would be expanded to other areas of drug discovery and development, with a focus on affordable healthcare.
Dr. Radha Rangarajan, Director, CSIR-CDRI, Lucknow said, "We are excited to work with Dr. Reddy’s for the development of APIs. Our shared goal of delivering high quality drug products, while ensuring affordability and access, makes this collaboration particularly meaningful.”
Deepak Sapra, Chief Executive Officer, API and Services, Dr. Reddy’s said, "We are delighted to collaborate with CSIR-CDRI and hope to foster deep industry-academia linkages. Such engagements allow for the best of public-private infrastructure, talent and knowledge to be harnessed for global health. The collaboration also aligns with our patient goals of serving 1.5 billion patients by 2030 globally, and launch innovative products with increased accessibility and affordability.”